RNAi-based therapies for Huntington's disease: delivery challenges and opportunities.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Therapeutic delivery

• Publication date

  2012-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4155/TDE.12.80PMID 23035592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficient and safe delivery of siRNA using anionic lipids: Formulation optimization studies.

  2012cited by this paper
• Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

  2012cited by this paper
• Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study

  2012cited by this paper
• An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

  2012cited by this paper
• Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis

  2012cited by this paper
• Cell-penetrating peptides: classes, origin, and current landscape.

  2012cited by this paper
• A stringent yeast two-hybrid matrix screening approach for protein-protein interaction discovery.

  2012cited by this paper
• Cell-penetrating peptides for the delivery of nucleic acids

  2012cited by this paper
• Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.

  2012cited by this paper
• Research progress on siRNA delivery with nonviral carriers

  2011cited by this paper
• Potential drugs and methods for preventing or delaying the progression of Huntington's disease.

  2011cited by this paper
• Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

  2011cited by this paper
• Huntington's disease: From molecular basis to therapeutic advances.

  2011cited by this paper
• SiRNA delivery with exosome nanoparticles

  2011cited by this paper
• Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

  2011cited by this paper
• Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

  2011cited by this paper
• Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.

  2011cited by this paper
• Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

  2011cited by this paper
• Recent advances of siRNA delivery by nanoparticles

  2011cited by this paper
• Mechanisms of Cellular Uptake of Cell-Penetrating Peptides

  2011cited by this paper
• Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrPC on Neuronal Cells and PrPRES in Infected Cell Cultures

  2010cited by this paper
• Biomolecules under mechanical force

  2010cited by this paper
• Huntington’s disease: pathogenesis to animal models

  2010cited by this paper
• Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

  2010cited by this paper
• Baculovirus vector-mediated transfer of NIS gene into colon tumor cells for radionuclide therapy.

  2010cited by this paper
• Symptomatic Treatment and Management of Huntington's Disease: An Overview

  2010cited by this paper
• RNAi therapeutics for CNS disorders.

  2010cited by this paper
• Selective gene silencing by viral delivery of short hairpin RNA

  2010cited by this paper
• A status report on RNAi therapeutics

  2010cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• Progress and challenges in RNA interference therapy for Huntington disease.

  2009cited by this paper
• Viral vectors: from virology to transgene expression

  2009cited by this paper
• Delivery of small-interfering RNA (siRNA) to the brain

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development

  2009cited by this paper
• Biological barriers to therapy with antisense and siRNA oligonucleotides.

  2009cited by this paper
• Strategies for targeted nonviral delivery of siRNAs in vivo.

  2009cited by this paper
• siRNA vs. shRNA: similarities and differences.

  2009cited by this paper
• Widespread changes in protein synthesis induced by microRNAs

  2008cited by this paper
• Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments

  2008cited by this paper
• Huntington’s disease: roles of huntingtin‐interacting protein 1 (HIP‐1) and its molecular partner HIPPI in the regulation of apoptosis and transcription

  2008cited by this paper
• Distinct uptake routes of cell-penetrating peptide conjugates.

  2008cited by this paper
• AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

  2008cited by this paper
• Cationic lipids and polymers mediated vectors for delivery of siRNA.

  2007cited by this paper
• RNAi therapeutics: principles, prospects and challenges.

  2007cited by this paper
• Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway

  2007cited by this paper
• Strategies for silencing human disease using RNA interference

  2007cited by this paper
• Molecular genetics of Huntington's Disease: When size does matter

  2007cited by this paper
• Interfering with disease: a progress report on siRNA-based therapeutics

  2007cited by this paper
• Nonviral delivery of synthetic siRNAs in vivo.

  2007cited by this paper
• Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.

  2007cited by this paper
• Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

  2007cited by this paper
• Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

  2007cited by this paper
• High-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In Vivo

  2007cited by this paper
• Liposomal Formulations for Nucleic Acid Delivery

  2007cited by this paper
• Chemical modification: the key to clinical application of RNA interference?

  2007cited by this paper
• Pharmaceutical, cellular and genetic therapies for Huntington's disease.

  2006cited by this paper
• Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs

  2006cited by this paper
• siRNA and isRNA: two edges of one sword.

  2006cited by this paper
• 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets

  2006cited by this paper
• siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene

  2006cited by this paper
• rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

  2006cited by this paper
• Multiple pathways contribute to the pathogenesis of Huntington disease

  2006cited by this paper
• Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it?

  2006cited by this paper
• Adenovirus-Mediated Silencing of Huntingtin Expression by shRNA

  2005cited by this paper
• Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

  2005cited by this paper
• A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites

  2005cited by this paper
• Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7

  2005cited by this paper
• siRNA therapeutics: big potential from small RNAs

  2005cited by this paper
• RNA interference in biology and disease.

  2005cited by this paper
• RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

  2005cited by this paper
• Physiology of the blood–brain barrier and its consequences for drug transport to the brain

  2005cited by this paper
• Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.

  2005cited by this paper
• Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

  2005cited by this paper
• Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

  2004cited by this paper
• Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.

  2004cited by this paper
• Unlocking the potential of the human genome with RNA interference

  2004cited by this paper
• Argonaute2 Is the Catalytic Engine of Mammalian RNAi

  2004cited by this paper
• Transcription and processing of human microRNA precursors.

  2004cited by this paper
• Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-( 1 , 4 , 5 ) Triphosphate

  2003cited by this paper
• RNA Interference in Biology and Medicine

  2003cited by this paper
• RNA Interference: Biology, Mechanism, and Applications

  2003cited by this paper
• Specific inhibition of Huntington's disease gene expression by siRNAs in cultured cells.

  2003cited by this paper
• Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing

  2003cited by this paper
• Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs.

  2003cited by this paper
• Apoptosis in Huntington's disease.

  2003cited by this paper
• Transcriptional abnormalities in Huntington disease.

  2003cited by this paper
• Progress and problems with the use of viral vectors for gene therapy

  2003cited by this paper
• Expression profiling reveals off-target gene regulation by RNAi

  2003cited by this paper
• Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.

  2003cited by this paper
• Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease

  2002cited by this paper
• Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

  2002cited by this paper
• Polyglutamine expansion neurodegenerative disease.

  2001cited by this paper
• Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Huntingtin Interacting Protein 1 Induces Apoptosis via a Novel Caspase-dependent Death Effector Domain*

  2000cited by this paper
• Transcriptional dysregulation in Huntington's disease.

  2000cited by this paper
• Fourteen and counting: unraveling trinucleotide repeat diseases.

  2000cited by this paper
• Recent advances in understanding the pathogenesis of Huntington's disease.

  1999cited by this paper

• In Vitro Efficacy of PEI-Derived Lipopolymers in Silencing of Toxic Proteins in a Neuronal Model of Huntington’s Disease

  2025cites this paper
• Nanotechnology-driven approaches for the management of Huntington's disease

  2025cites this paper
• Investigation into pathological neuronal-myeloid cell interactions and rescue of hyper-reactive immune responses in Huntington's disease

  2017cites this paper
• Soft Computing Approach for Optimization of siRNA Efficiency Prediction for Post transcriptional Gene Silencing

  2016cites this paper
• Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome

  2016cites this paper
• Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy

  2015cites this paper
• Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

  2015cites this paper
• Stem cells for cell replacement therapy: A therapeutic strategy for HD?

  2014cites this paper
• Rare-disease genetics in the era of next-generation sequencing: discovery to translation

  2013cites this paper
• RNA Interference: A Recent Approach for the Remedy of Various Diseases

  2013cites this paper